Hoo JJ, Shrimpton AE Distal 3p deletion is not necessarily associated with dysmorphic features or psychomotor delay. Am J Med Genet A. 2008 Feb 15;146A(4):538. doi: 10.1002/ajmg.a.32158. No abstract available.
Hoo JJ, Shrimpton AE Familial hyper- and hypopigmentation with age-related pattern change. Am J Med Genet A. 2005 Jan 15;132A(2):215-8. doi: 10.1002/ajmg.a.30381. No abstract available.
LaDine BJ, Simmons JA, Shrimpton AE, Hoo JJ Syndrome of short stature, widow's peak, ptosis, posteriorly angulated ears, and joint problems: exclusion of the Aarskog (FGD1) gene as a candidate gene. Am J Med Genet. 2001 Mar 15;99(3):248-51. doi: 10.1002/
Shrimpton AE, Braddock BR, Hoo JJ Narrowing the map of a gene (MRXS9) for X-linked mental retardation, microcephaly, and variably short stature at Xq12-q21.31. Am J Med Genet. 2000 May 15;92(2):155-6. No abstract available.
Shrimpton AE, Braddock BR, Thomson LL, Stein CK, Hoo JJ Molecular delineation of deletions on 2q37.3 in three cases with an Albright hereditary osteodystrophy-like phenotype. Clin Genet. 2004 Dec;66(6):537-44. doi: 10.1111/j.1399-0004.2004.00363.x.
Shrimpton AE, Daly KM, Hoo JJ Mapping of a gene (MRXS9) for X-linked mental retardation, microcephaly, and variably short stature to Xq12-q21.31. Am J Med Genet. 1999 May 28;84(3):293-9.
Shrimpton AE, Jensen KA, Hoo JJ Karyotype-phenotype analysis and molecular delineation of a 3p26 deletion/8q24.3 duplication case with a virtually normal phenotype and mild cognitive deficit. Am J Med Genet A. 2006 Feb 15;140(4):388-91. doi: 10.1002/ajmg
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.